R2 resection in pancreatic cancer -: does it make sense?

被引:25
作者
Koeninger, Joerg [1 ]
Wente, Moritz N. [1 ]
Mueller-Stich, Beat P. [1 ]
di Mola, Francesco F. [1 ]
Gutt, Carsten N. [1 ]
Hinz, Ulf [1 ]
Mueller, Michael W. [1 ]
Friess, Helmut [1 ]
Buechler, Markus W. [1 ]
机构
[1] Univ Heidelberg, Dept Surg, D-69120 Heidelberg, Germany
关键词
pancreatic cancer; pancreatic surgery; R2; resection;
D O I
10.1007/s00423-008-0308-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background The goal of surgical treatment in patients with pancreatic cancer is the complete resection of tumor tissue; however, the intraoperative appraisal of resectability can be difficult. Extensive surgical exploration for definitive clear resectability may lead to R2 resections in single cases. Patients We analyzed 38 patients with pancreatic cancer with remaining macroscopic tumor tissue after pancreatic resection, as R0 resection was not possible. Patients were compared to 46 patients with unresectable cancer without distant metastases or peritoneal carcinomatosis, in which a bypass procedure was performed. Results Operating time and hospital stay were significantly longer after R2 resection. Intraoperative blood loss was significantly higher; and severe surgical complications and the need for relaparotomy were significantly more frequent after R2 resection. The 30-day mortality rate was higher after R2 resection; this difference was not statistically significant. Median survival was comparable in both groups. Two years after surgery, 22.6% of the patients after R2 resection were still alive compared to 10.9% after bypass surgery. Conclusion Tumor debulking is not a treatment option in patients with advanced pancreatic cancer, but the patient is not at a disadvantage compared to bypass procedures if tumor tissue remains and R0 resection cannot be achieved after surgical exploration.
引用
收藏
页码:929 / 934
页数:6
相关论文
共 23 条
[1]  
Chao C, 2000, AM SURGEON, V66, P378
[2]   Are there indications for palliative resection in pancreatic cancer? [J].
Gouma, DJ ;
van Dijkum, EJMN ;
van Geenen, RCI ;
van Gulik, TM ;
Obertop, H .
WORLD JOURNAL OF SURGERY, 1999, 23 (09) :954-959
[3]  
GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO
[4]  
2-V
[5]  
Huguier M, 1996, HEPATO-GASTROENTEROL, V43, P721
[6]  
Johnstone PAS, 1996, J SURG ONCOL, V61, P7, DOI 10.1002/(SICI)1096-9098(199601)61:1<7::AID-JSO2>3.0.CO
[7]  
2-H
[8]   Pancreatic tumor cells influence the composition of the extracellular matrix [J].
Köninger, J ;
Giese, T ;
di Mola, FF ;
Wente, MN ;
Esposito, I ;
Bachem, MG ;
Giese, NA ;
Büchler, MW ;
Friess, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 322 (03) :943-949
[9]   Microscopically incomplete resection offers acceptable palliation in pancreatic cancer [J].
Kuhlmann, K ;
de Castro, S ;
van Heek, T ;
Busch, O ;
van Gulik, T ;
Obertop, H ;
Gouma, D .
SURGERY, 2006, 139 (02) :188-196
[10]   Pancreaticoduodenectomy - Does it have a role in the palliation of pancreatic cancer? [J].
Lillemoe, KD ;
Cameron, JL ;
Yeo, CJ ;
Sohn, TA ;
Nakeeb, A ;
Sauter, PK ;
Hruban, RH ;
Abrams, RA ;
Pitt, HA .
ANNALS OF SURGERY, 1996, 223 (06) :718-725